Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.
A study of multiple biosimilar switches for patients with a variety of rheumatic musculoskeletal diseases (RMDs) demonstrated a high rate of patient retention (89%) and no major changes in disease activity or function, investigators reported at the American College of Rheumatology Convergence 2020 meeting.
Sufficient information is available to elucidate the safety and efficacy of a single switch from an originator to a biosimilar product in the treatment of RMDs, but “The effect of multiple switching between biosimilars of the same reference product has not been thoroughly investigated to date,” investigators said.
Biosimilars are available at significant discounts to reference products, and the more biosimilars that are available, the more attractive multiple switching becomes, as providers and patients look for the most affordable treatment; hence, the significance of the study, investigators said.
The retrospective study enrolled 100 patients with rheumatoid arthritis (n = 54), axial spondyloarthritis (n = 27), and psoriatic arthritis (n = 19) who switched to 2 etanercept biosimilars for economic reasons over a 21.1-month average follow-up period. The switches (first, Benepali, SB4; second, Erelzi, GP2015) included in the study began in 2017, and the end of the observation period was October 2019.
Disease activity, function, and adverse events (AEs) were assessed regularly, and the primary end point was scores documented at week 12 after the second switch. The composite Disease Activity Score-28 and the Stanford Health Assessment Questionnaire Disability Index were used to measure changes in rheumatoid arthritis and psoriatic arthritis. Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, and Ankylosing Spondylitis Disease Activity Score were used for axial spondyloarthritis.
The 89% retention rate was observed about 6 months after the second switch. Seven patients discontinued due to inefficacy or AEs, 2 were lost to follow-up, and 1 patient died (cardiac arrest).
Investigators said 14 AEs were reported in 8 patients; and among those patients, 4 resumed treatment with reference etanercept in month 6; one patient was successfully retreated with Erelzi in month 3 after experiencing mucosal erosions; and 3 patients were switched to other forms of medication. Week 12 scores for disease activity and function were unchanged.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.